Features associated with different inflammatory phenotypes of calcium pyrophosphate deposition (CPPD) disease: study using data from the international ACR/EULAR CPPD classification criteria cohort.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
01 Aug 2024
Historique:
revised: 03 07 2024
received: 21 05 2024
accepted: 24 07 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 1 8 2024
Statut: aheadofprint

Résumé

To examine the disease, demographic, and imaging features associated with different inflammatory phenotypes of calcium pyrophosphate deposition (CPPD) disease i.e., recurrent acute CPP crystal arthritis, chronic CPP crystal inflammatory arthritis, and crowned dens syndrome (CDS). Data from an international cohort assembled from 25 sites in 7 countries for the development and validation of the 2023 ACR/EULAR CPPD classification criteria, that met the criteria were included. Three cross-sectional studies were conducted to determine the phenotypic characteristics of recurrent acute CPP crystal arthritis, chronic CPP crystal inflammatory arthritis, and CDS. Multivariable logistic regression analysis was used to calculate the adjusted odds ratios (aOR) and 95% confidence intervals (CIs) to examine the association between potential risk factors and the inflammatory phenotype. Among the 618 people included ((56% female), mean age (standard deviation (S.D.)) 74.0 (11.9) years), 602 (97.4%) had experienced acute CPP crystal arthritis, 332 (53.7%) had recurrent acute arthritis, 158 (25.6%) had persistent inflammatory arthritis, and 45 (7.3%), had had CDS. Recurrent acute CPP crystal arthritis associated with longer disease duration (aOR 2.88 (95%CI 2.00;4.14)). Chronic CPP crystal inflammatory arthritis was associated with ). acute wrist arthritis (aOR(95%CI) 2.92(1.81-4.73)), metacarpophalangeal (aOR(95% CI) 1.87(1.17-2.97)) and scapho-trapezio-trapezoid (STT) joint osteoarthritis (aOR(95% CI) 1.83(1.15-2.91)), and negatively associated with either metabolic or familial risk for CPPD (aOR(95% CI) 0.60(0.37-0.96). CDS was associated with male sex (aOR(95% CI) 2.35(1.21-4.59)), STT joint osteoarthritis (aOR(95% CI) 2.71(1.22-6.05)), and more joints affected with chondrocalcinosis (aOR(95% CI) 1.46(1.15-1.85)). CPPD disease encompasses acute and chronic inflammatory phenotypes, each with specific clinical and imaging features which need to be considered in the diagnostic workup.

Identifiants

pubmed: 39087364
doi: 10.1002/art.42962
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

This article is protected by copyright. All rights reserved.

Auteurs

Tristan Pascart (T)

Department of Rheumatology, Lille Catholic University, Saint-Philibert Hospital, Lille, France.

Augustin Latourte (A)

Université Paris Cité, INSERM, UMR-S 1132 BIOSCAR, and Service de Rhumatologie, AP-HP, Lariboisière Hospital, Paris, France.

Sara K Tedeschi (SK)

Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

Nicola Dalbeth (N)

Department of Medicine, University of Auckland, Auckland, New Zealand.

Tuhina Neogi (T)

Department of Medicine, Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts.

Antonella Adinolfi (A)

Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Uri Arad (U)

Department of Rheumatology, Te Whatu Ora-Health New Zealand Waikato, and Waikato Clinical School, University of Auckland, Hamilton, New Zealand.

Mariano Andres (M)

Department of Medicine, Rheumatology Section, Hospital General Universitario Dr. Balmis-ISABIAL, Universidad Miguel Hernández, Alicante, Spain.

Fabio Becce (F)

Department of Diagnostic and Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Thomas Bardin (T)

Institut Mutualiste Montsouris, Paris, France.

Edoardo Cipolletta (E)

Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic, University of Marche, Ancona, Italy.
Academic Rheumatology, University of Nottingham, Nottingham, UK.

Hang-Korng Ea (HK)

Université Paris Cité, INSERM, UMR-S 1132 BIOSCAR, and Service de Rhumatologie, AP-HP, Lariboisière Hospital, Paris, France.

Georgios Filippou (G)

Rheumatology Department, IRCCS Istituto Ortopedico Galeazzi & Department of Biomedical and Clinical Sciences, University of Milan Milan, Italy.

Emilio Filippucci (E)

Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic, University of Marche, Ancona, Italy.

John FitzGerald (J)

University of California, and Veterans Administration for Greater Los Angeles, Los Angeles, California.

Annamaria Iagnocco (A)

Academic Rheumatology Center, Università degli Studi di Torino, Turin, Italy.

Tim L Jansen (TL)

VieCuri Medical Centre, Venlo, The Netherlands, and Medical Cell BioPhysics Group, University of Twente, Enschede, The Netherlands.

Matthijs Janssen (M)

VieCuri Medical Centre, Venlo, The Netherlands, and Medical Cell BioPhysics Group, University of Twente, Enschede, The Netherlands.

Frédéric Lioté (F)

Department of Rheumatology, Feel'Gout, GH Paris Saint-Joseph & Université Paris Cité, INSERM, UMR-S 1132 BIOSCAR, Paris, France.

Alexander So (A)

Lausanne University Hospital, Lausanne, Switzerland.

Geraldine M McCarthy (GM)

School of Medicine and Medical Science, University College Dublin, and Mater Misericordiae University Hospital, Dublin, Ireland.

Roberta Ramonda (R)

Rheumatology Unit, Department of Medicine, DIMED, University of Padova, Padova, Italy.

Pascal Richette (P)

Université Paris Cité, INSERM, UMR-S 1132 BIOSCAR, and Service de Rhumatologie, AP-HP, Lariboisière Hospital, Paris, France.

Ann Rosenthal (A)

Department of Medicine, Medical College of Wisconsin, Milwaukee.

Carlo Scirè (C)

Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy.

Ettore Silvagni (E)

Section of Rheumatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy, and Azienda Ospedaliera-Universitaria di Ferrara, Cona (FE), Italy.

Silvia Sirotti (S)

Rheumatology Department, IRCCS Istituto Ortopedico Galeazzi & Department of Biomedical and Clinical Sciences, University of Milan Milan, Italy.

Francisca Sivera (F)

Department of Rheumatology, Hospital General Universitario Elda, Elda, Spain, and Department of Clinical Medicine, Universidad Miguel Hernandez, Elche, Spain.

Lisa K Stamp (LK)

University of Otago Christichurch, Christchurch, and Te Whatu Ora Waitata, Christchurch, New-Zealand.

William J Taylor (WJ)

Department of Medicine, University of Otago, Wellington, New Zealand.

Robert Terkeltaub (R)

University of California, San Diego.

Hyon K Choi (HK)

Harvard Medical School, Boston, Massachusetts.

Abhishek Abhishek (A)

Academic Rheumatology, University of Nottingham, Nottingham, UK.

Classifications MeSH